EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China

Xiaowen Liu, Jiejie Jin, Menglong Zhou, Ye Zhou, Hong Cai, Hua Huang, Min Yan, Zhongyin Yang, Runhua Feng, Qi Lu, Hao Ding, Hongtao Xu und 7 weitere

Cancer Communications · 2026

DOI: 10.34133/cancomm.0006 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer Communications, 2026. Verfasst von Xiaowen Liu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, P. R. China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Esophagogastric Junction, Esophageal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognostic superiority of preoperative chemoradiotherapy (pre-CRT) over preoperative chemotherapy (pre-CT) in patients with locally advanced gastric cancer remains controversial. Herein, we evaluated the efficacy and safety of pre-CRT relative to those of pre-CT in this cohort.

Methods

This open-label, phase III, randomized controlled trial was conducted at 4 medical centers in China. Eligible patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma were randomly assigned (1:1) to receive either 3 cycles of oxaliplatin and S-1 (SOX), followed by surgery and 3 postoperative cycles of SOX (pre-CT), or 1 cycle of SOX, followed by concurrent chemoradiotherapy, a second cycle of SOX, surgery, and 3 postoperative cycles of SOX (pre-CRT). The primary endpoint was 3-year disease-free survival (DFS). Secondary endpoints included 3-year overall survival (OS), R0 resection rate, pathological complete response (pCR) rate, treatment-related toxicity, and postoperative complications.

Results

Due to premature trial termination, only 204 patients were enrolled, and an efficacy analysis was conducted on 194 eligible patients. The baseline characteristics were well balanced between the 2 groups. The DFS and OS were indistinguishable between the 2 groups. The 3-year DFS rates were 53.6% in the pre-CRT group and 53.9% in the pre-CT group [hazard ratio (HR), 1.02; 95% confidence interval (CI), 0.70 to 1.50; log-rank P = 0.913]. The 3-year OS rates were 62.8% in the pre-CRT group and 60.5% in the pre-CT group (HR, 0.97; 95% CI, 0.63 to 1.47; log-rank P = 0.874). The R0 resection rates were 81.0% and 74.5% in the pre-CRT and pre-CT groups, respectively. Additionally, the pCR rate was higher in the pre-CRT group (12.0%) than in the pre-CT group (2.1%). Treatment-related toxic effects were comparable between the 2 groups.

Conclusion

This trial did not demonstrate a survival advantage for pre-CRT over pre-CT in patients with locally advanced gastric or gastroesophageal adenocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAdenocarcinomaEsophagogastric JunctionEsophageal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyHumansFemaleMaleChinaMiddle AgedAgedOxaliplatinNeoadjuvant TherapyAdultTegafurOxonic AcidPathologic Complete ResponseTreatment OutcomeDisease-Free SurvivalDrug Combinations

Substanzen

OxaliplatinTegafurOxonic AcidS 1 (combination)Drug Combinations

Autor:innen und Institutionen

  • Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
  • Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, P. R. China.
  • Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
  • Shanghai Key Laboratory of Radiation Oncology, Fudan University, Shanghai, P. R. China.
  • Department of Gastrointestinal Surgery, Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory of Stomach Neoplasm, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P. R. China.
  • Department of Surgery, Huadong Hospital, Fudan University, Shanghai, P. R. China.

ORCID-Profile: Yanong Wang

Zitieren

APA

Liu, X., Jin, J., Zhou, M., Zhou, Y., Cai, H., Huang, H., Yan, M., Yang, Z., Feng, R., Lu, Q., Ding, H., Xu, H., Liu, X., Li, G., Zhu, H., Sheng, W., Yang, X., Zhang, Z., & Wang, Y. (2026). Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China. Cancer Communications. https://doi.org/10.34133/cancomm.0006

Vancouver

Liu X, Jin J, Zhou M, Zhou Y, Cai H, Huang H, et al. Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China. Cancer Communications. 2026. doi:10.34133/cancomm.0006

BibTeX
@article{Liu2026,
  author = {Liu, Xiaowen and Jin, Jiejie and Zhou, Menglong and Zhou, Ye and Cai, Hong and Huang, Hua and Yan, Min and Yang, Zhongyin and Feng, Runhua and Lu, Qi and Ding, Hao and Xu, Hongtao and Liu, Xuexiao and Li, Guichao and Zhu, Hui and Sheng, Weiqi and Yang, Xiujiang and Zhang, Zhen and Wang, Yanong},
  title = {Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China},
  journal = {Cancer Communications},
  year = {2026},
  doi = {10.34133/cancomm.0006}
}
Kostenlos starten →